SHL Telemedicine

Company Overview

Snapshot

Founded in January 1987 by Yariv Alroy, SHL Telemedicine operates with 51–200 employees. The company has raised a total of $109 million across three funding rounds and is publicly traded on SIX and NASDAQ. In March 2023, SHL Telemedicine commenced trading on NASDAQ.

Business overview

SHL Telemedicine develops home-based heart-monitoring systems, including ECG devices, platforms, and software, designed to improve survival rates and quality of life for users after cardiac events. Its systems are intuitive and compact, capable of recording 12 hospital-grade ECGs within seconds. The company's core offering includes a 24/7 telemedicine center staffed by medical professionals for evaluation and care, and it provides users with secure personal health records. SHL Telemedicine operates in the Health Tech & Life Sciences sector, focusing on digital healthcare, patient remote monitoring, medical devices, and diagnostics devices, serving patients, providers, and insurance companies across Europe, the United States, Germany, China, and India.

Strategic signal

In May 2024, SHL Telemedicine expanded its offering in Israel with a groundbreaking at-home biomarker blood test and officially launched its SmartHeart Direct-to-Consumer Membership in the US. These developments signal a strategic push towards broadening its diagnostic capabilities and enhancing direct patient engagement, indicating a focus on market expansion and accessible healthcare solutions.

Company Intelligence Q&A

When did SHL Telemedicine commence trading on NASDAQ?

SHL Telemedicine commenced trading on NASDAQ in March 2023 under the ticker symbol SHLT.

What significant product launch did SHL Telemedicine announce in May 2024?

In May 2024, SHL Telemedicine expanded its offering in Israel with a groundbreaking at-home biomarker blood test and officially launched its SmartHeart® Direct-to-Consumer membership in the US.

What were the key findings from the SmartHeart® technology trials in September 2023?

In September 2023, SHL Telemedicine's SmartHeart® technology showed remarkable effects in trials conducted by Mayo Clinic and Imperial College London.

What strategic move did SHL Telemedicine make in the US in November 2023?

In November 2023, SHL Telemedicine established a US Nationwide Cardiology Network for ECG interpretations and telehealth visits, further advancing its direct-to-consumer strategy.

What acquisition did SHL Telemedicine complete in August 2021?

In August 2021, SHL Telemedicine acquired a majority stake in Mediton Group, a leading B2B healthcare services provider in Israel.